Biomarkers Market

Biomarkers Market (Type: Safety Biomarkers, Susceptibility/Risk Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Monitoring Biomarkers, Predictive Biomarkers, and Pharmacodynamic/Response Biomarkers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Biomarkers Market Outlook

  • The global industry was valued at US$ 51.2 Bn in 2022
  • It is projected to advance at a CAGR of 10.4% from 2023 to 2031 and reach more than US$ 125.6 Bn by the end of 2031

Analysts’ Viewpoint

The escalating global occurrence of chronic illnesses such as cardiovascular ailments, cancers, diabetes, and neurological disorders has intensified the need for timely disease detection, precise diagnostics, and tailored treatment methods, which is bolstering the biomarkers market growth.

Furthermore, the advent of personalized medicine and precision diagnostics has highlighted the importance of biomarkers in categorizing patients, selecting treatments, and monitoring therapeutic progress.

Technological advancements and the launch of more precise and effective diagnostic assays also play a key role in market expansion.

Additionally, supportive regulatory frameworks, surge in investments in healthcare research and development, and collaborations among academic institutions, pharmaceutical firms, and diagnostic companies have spurred innovation in biomarker identification and application, which is expected to offer lucrative biomarkers market opportunities during the forecast period.

Market Outlook

The biomarkers market covers a broad range of measurable signals, such as genetic variances, protein levels, and biochemical alterations, which indicate biological functions, disease conditions, or responses to therapies. Biomarkers have a critical role across various sectors, including diagnostics, drug exploration, personalized medicine, and clinical studies.

Significant progress in technology has notably reshaped the biomarkers arena, resulting in the introduction of more precise, sensitive, and high-capacity assays.

Next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, mass spectrometry, and other advanced methods facilitate the identification and measurement of biomarkers with unparalleled accuracy and efficacy.

These advancements have transformed disease detection, patient categorization, treatment choice, and therapeutic monitoring, thus fueling market progress.

Attribute Detail
Drivers
  • Rise in Prevalence of Chronic Diseases
  • Increase in Significance of Companion Diagnostics

Rise in Prevalence of Chronic Diseases Boosting Biomarkers Market Size

Biomarkers, which are measurable signs in the body, play a key role in detecting chronic diseases and conditions such as heart disease, cancer, diabetes, and neurological disorders early and monitoring how they progress.

They give important information about a person's health, how the disease is progressing, and how well they respond to treatment, which is crucial for personalized healthcare.

According to the World Health Organization, non-communicable diseases (NCDs) cause 74% of all deaths worldwide, with cardiovascular diseases being the leading cause, followed by cancer, chronic respiratory diseases, and diabetes.

In the United States, 60% of people have at least one chronic condition, such as heart disease or diabetes, which are the main causes of death and disability.

In India, 21% of older adults have at least one chronic disease, with high rates in rural areas compared to urban ones. Hypertension and diabetes are the most common chronic diseases in India, especially in Kerala, Andhra Pradesh, West Bengal, and Goa.

By helping detect diseases early, improving diagnosis accuracy, and supporting personalized medicine, biomarkers play a crucial role in tackling the increasing burden of chronic diseases worldwide.

Increase in Significance of Companion Diagnostics Driving Biomarkers Market Demand

The rise of companion diagnostics in the biomarkers market is changing the approach toward personalized medicine. These tools help doctors match treatments with specific biomarkers in patients, making treatments more targeted and effective. Companion diagnostics look at genetic differences or protein levels in patients to create personalized treatment plans.

They give doctors the information they need to choose the best treatment for each patient. People are being afflicted with complex conditions such as cancer that need better treatment options.

Companion diagnostics help doctors figure out which patients will respond best to certain treatments, which can reduce side effects and make treatments work better.

In personalized medicine, companion diagnostics help separate patients into groups based on how they respond to drugs. This helps doctors understand which treatments work best for different groups of patients.

This separation is based on how the treatment works and is studied through research or clinical trials, making medical treatments more precise and effective. Thus the importance of biomarkers in companion diagnostics is a major market catalyst.

High Demand for Consumables

In terms of product & service, the global biomarkers market segmentation includes consumables, equipment, and services. The consumables segment is expected to dominate during the forecast period.

Biomarker assays typically require consumables such as reagents, kits, and other laboratory supplies for sample preparation, analysis, and detection.

These consumables are essential to conduct research and diagnostics related to biomarkers, which serve as vital indicators of biological processes, disease states, or responses to therapies.

Ongoing research in personalized medicine, oncology, neurology, and cardiovascular diseases is spurring the demand for consumables in the biomarkers market. Furthermore, the surge in prevalence of chronic diseases and the growth in emphasis on early disease detection and prevention are boosting market dynamics.

Diagnostics Application Gaining Traction in the Market

Based on application, the market is classified into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and others.

As per the biomarkers industry report, the diagnostics segment commands a substantial market share and is experiencing rapid growth. Biomarkers act as measurable signals of biological functions, disease conditions, or responses to treatments, providing crucial insights for diagnostic applications.

As chronic diseases become more prevalent and personalized medicine gains prominence, the need for biomarker-based diagnostics is increasing. These tools empower healthcare providers to detect diseases early, track their advancement, and customize treatment plans for each patient.

Furthermore, ongoing technological advancements have led to the launch of more precise and effective diagnostic tests, encouraging the widespread adoption of biomarker-based diagnostics across diverse medical fields.

Rise in Cancer Cases Globally Driving Market Statistics

In terms of disease indication, the biomarkers market has been divided into cancer, neurological disorders, cardiovascular disorders, infectious diseases, immune disorders, and others.

As per biomarkers market trends, the cancer disease indication segment is anticipated to lead in the next few years. Cancer remains a significant cause of mortality worldwide, with nearly 10 million deaths reported in 2020, representing approximately one-sixth of all fatalities, as per the World Health Organization.

Common cancer types include lung, breast, colon, rectal, and prostate cancers. Lifestyle factors such as tobacco use, obesity, excessive alcohol consumption, poor diet, and sedentary behavior contribute to around one-third of cancer-related deaths. Surge in incidence of cancer, particularly lung cancer globally, serves as a significant driver for this segment.

Regional Outlook of Biomarkers Industry

Attribute Detail
Leading Region North America

North America is expected to emerge as a highly profitable market during the forecast period. The region's substantial disease burden, widespread acceptance of biomarkers for diagnostic, drug development, and prognostic applications, and a notable increase in research funding are boosting the North America biomarkers market share.

The region is further likely to benefit from an upsurge in product launches and high demand for biomarkers, contributing positively to the regional market's growth trajectory.

Europe is seeing an increase in focus on personalized medicine and precise diagnostics, which depend extensively on biomarkers for categorizing patients, selecting treatments, and monitoring therapeutic outcomes.

Additionally, favorable regulatory environments and rise in investments in healthcare research and development are driving market development in the region.

Asia Pacific is grappling with a mounting burden of cancer, with projections indicating a substantial rise in new cases by 2030 compared to 2020. To access more tailored and effective treatments, an increasing number of patients are undergoing biomarker testing.

With the escalating incidence of cancer, molecular testing technologies such as next-generation sequencing (NGS) and PCR-based molecular diagnostics (MDx) are gaining considerable importance in the region.

Analysis of Key Players

The global biomarkers market is fragmented with the presence of several players. Abbott Laboratories, Agilent Technology, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux SA (Astute Medical), Merck KGaA, Qiagen NV, Quanterix, Quest Diagnostics, and Thermo Fisher Scientific Inc. are the major biomarkers market manufacturers.

Key Developments

  • In February 2024, Abbott and Fujirebio announced a collaboration to create a neurofilament-light chain (Nf-L) neurology biomarker assay for use on Abbott's Alinity I, intended for research use only (RUO). Researchers who are conducting studies to show the utility of the Nf-L biomarker can access the RUO assay from Abbott. Numerous neurological conditions, such as multiple sclerosis, Alzheimer's, traumatic brain injury, and cognitive impairment, are the subject of ongoing research utilizing the Nf-L biomarker. Abbott and Fujirebio aim to release Abbott's Alinity I Nf-L research use only assay by 2025.
  • In May 2023, Thermo Fisher Scientific entered into a partnership agreement with Pfizer to expand localized access to next-generation sequencing (NGS)-based testing for cancer patients in international markets. NGS can be used to screen a single tumor tissue or blood sample for multiple biomarkers simultaneously, eliminating the need for multiple sequential, single-biomarker tests. It provides rapid and actionable genomic insights to help healthcare professionals make precision oncology treatment decisions for patients.

Each of these companies have been profiled in the biomarkers market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Global Biomarkers Market Snapshot

Attribute Detail
Market Size in 2022 US$ 51.2 Bn
Forecast Value in 2031 More than US$ 125.6 Bn
Growth Rate (CAGR) 10.4%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation
  • Product & Service
    • Consumables
    • Services
    • Equipment
  • Type
    • Safety Biomarkers
    • Susceptibility/Risk Biomarkers
    • Diagnostic Biomarkers
    • Prognostic Biomarkers
    • Monitoring Biomarkers
    • Predictive Biomarkers
    • Pharmacodynamic/Response Biomarkers
  • Application
    • Diagnostics
    • Drug Discovery & Development
    • Personalized Medicine
    • Disease Risk Assessment
    • Others
  • Disease Indication
    • Cancer
    • Neurological Disorders
    • Cardiovascular Disorders
    • Infectious Diseases
    • Immune Disorders
    • Others
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Abbott Laboratories
  • Agilent Technology
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • BioMerieux SA (Astute Medical)
  • Merck KGaA
  • Qiagen NV
  • Quanterix
  • Quest Diagnostics
  • Thermo Fisher Scientific Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global biomarkers market in 2022?

It was valued at US$ 51.2 Bn in 2022

How big will the biomarkers business be by 2031?

It is projected to reach more than US$ 125.6 Bn by the end of 2031

What will be the CAGR of the biomarkers industry during the forecast period?

The CAGR is anticipated to be 10.4% from 2023 to 2031

Which region will account for major share of the biomarkers sector during the forecast period?

North America is expected to account for largest share from 2023 to 2031

Who are the prominent biomarker providers?

Abbott Laboratories, Agilent Technology, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux SA (Astute Medical), Merck KGaA, Qiagen NV, Quanterix, Quest Diagnostics, and Thermo Fisher Scientific Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Biomarkers Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Biomarkers Market Analysis and Forecasts, 2017–2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Disease Prevalence & Incidence Rate Globally with Key Countries

        5.3. Regulatory Scenario by Region/globally

        5.4. COVID-19 Impact Analysis

    6. Global Biomarkers Market Analysis and Forecasts, By Product & Service

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Product & Service, 2017–2031

            6.3.1. Consumables

            6.3.2. Services

            6.3.3. Equipment

        6.4. Market Attractiveness By Product & Service

    7. Global Biomarkers Market Analysis and Forecasts, By Disease Indication

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Application, 2017–2031

            7.3.1. Diagnostics

            7.3.2. Drug Discovery & Development

            7.3.3. Personalized Medicine

            7.3.4. Disease Risk Assessment

            7.3.5. Others

        7.4. Market Attractiveness By Application

    8. Global Biomarkers Market Analysis and Forecasts, By Type

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Type, 2017–2031

            8.3.1. Safety Biomarkers

            8.3.2. Susceptibility/Risk Biomarkers

            8.3.3. Diagnostic Biomarkers

            8.3.4. Prognostic Biomarkers

            8.3.5. Monitoring Biomarkers

            8.3.6. Predictive Biomarkers

            8.3.7. Pharmacodynamic/Response Biomarkers

        8.4. Market Attractiveness By Type

    9. Global Biomarkers Market Analysis and Forecasts, By Disease Indication

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast By Disease Indication, 2017–2031

            9.3.1. Cancer

            9.3.2. Neurological Disorders

            9.3.3. Cardiovascular Disorders

            9.3.4. Infectious Diseases

            9.3.5. Immune Disorders

            9.3.6. Others

        9.4. Market Attractiveness By Disease Indication

    10. Global Biomarkers Market Analysis and Forecasts, By Region

        10.1. Key Findings

        10.2. Market Value Forecast By Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Region

    11. North America Biomarkers Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Product & Service, 2017–2031

            11.2.1. Consumables

            11.2.2. Services

            11.2.3. Equipment

        11.3. Market Value Forecast By Application, 2017–2031

            11.3.1. Diagnostics

            11.3.2. Drug Discovery & Development

            11.3.3. Personalized Medicine

            11.3.4. Disease Risk Assessment

            11.3.5. Others

        11.4. Market Value Forecast By Type, 2017–2031

            11.4.1. Safety Biomarkers

            11.4.2. Susceptibility/Risk Biomarkers

            11.4.3. Diagnostic Biomarkers

            11.4.4. Prognostic Biomarkers

            11.4.5. Monitoring Biomarkers

            11.4.6. Predictive Biomarkers

            11.4.7. Pharmacodynamic/Response Biomarkers

        11.5. Market Value Forecast By Disease Indication, 2017–2031

            11.5.1. Cancer

            11.5.2. Neurological Disorders

            11.5.3. Cardiovascular Disorders

            11.5.4. Infectious Diseases

            11.5.5. Immune Disorders

            11.5.6. Others

        11.6. Market Value Forecast By Country, 2017–2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Product & Service

            11.7.2. By Application

            11.7.3. By Type

            11.7.4. By Disease Indication

            11.7.5. By Country

    12. Europe Biomarkers Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Product & Service, 2017–2031

            12.2.1. Consumables

            12.2.2. Services

            12.2.3. Equipment

        12.3. Market Value Forecast By Application, 2017–2031

            12.3.1. Diagnostics

            12.3.2. Drug Discovery & Development

            12.3.3. Personalized Medicine

            12.3.4. Disease Risk Assessment

            12.3.5. Others

        12.4. Market Value Forecast By Type, 2017–2031

            12.4.1. Safety Biomarkers

            12.4.2. Susceptibility/Risk Biomarkers

            12.4.3. Diagnostic Biomarkers

            12.4.4. Prognostic Biomarkers

            12.4.5. Monitoring Biomarkers

            12.4.6. Predictive Biomarkers

            12.4.7. Pharmacodynamic/Response Biomarkers

        12.5. Market Value Forecast By Disease Indication, 2017–2031

            12.5.1. Cancer

            12.5.2. Neurological Disorders

            12.5.3. Cardiovascular Disorders

            12.5.4. Infectious Diseases

            12.5.5. Immune Disorders

            12.5.6. Others

        12.6. Market Value Forecast By Country/Sub-region, 2017–2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Product & Service

            12.7.2. By Application

            12.7.3. By Type

            12.7.4. By Disease Indication

            12.7.5. By Country/Sub-region

    13. Asia Pacific Biomarkers Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Product & Service, 2017–2031

            13.2.1. Consumables

            13.2.2. Services

            13.2.3. Equipment

        13.3. Market Value Forecast By Application, 2017–2031

            13.3.1. Diagnostics

            13.3.2. Drug Discovery & Development

            13.3.3. Personalized Medicine

            13.3.4. Disease Risk Assessment

            13.3.5. Others

        13.4. Market Value Forecast By Type, 2017–2031

            13.4.1. Safety Biomarkers

            13.4.2. Susceptibility/Risk Biomarkers

            13.4.3. Diagnostic Biomarkers

            13.4.4. Prognostic Biomarkers

            13.4.5. Monitoring Biomarkers

            13.4.6. Predictive Biomarkers

            13.4.7. Pharmacodynamic/Response Biomarkers

        13.5. Market Value Forecast By Disease Indication, 2017–2031

            13.5.1. Cancer

            13.5.2. Neurological Disorders

            13.5.3. Cardiovascular Disorders

            13.5.4. Infectious Diseases

            13.5.5. Immune Disorders

            13.5.6. Others

        13.6. Market Value Forecast By Country/Sub-region, 2017–2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Product & Service

            13.7.2. By Application

            13.7.3. By Type

            13.7.4. By Disease Indication

            13.7.5. By Country/Sub-region

    14. Latin America Biomarkers Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Product & Service, 2017–2031

            14.2.1. Consumables

            14.2.2. Services

            14.2.3. Equipment

        14.3. Market Value Forecast By Application, 2017–2031

            14.3.1. Diagnostics

            14.3.2. Drug Discovery & Development

            14.3.3. Personalized Medicine

            14.3.4. Disease Risk Assessment

            14.3.5. Others

        14.4. Market Value Forecast By Type, 2017–2031

            14.4.1. Safety Biomarkers

            14.4.2. Susceptibility/Risk Biomarkers

            14.4.3. Diagnostic Biomarkers

            14.4.4. Prognostic Biomarkers

            14.4.5. Monitoring Biomarkers

            14.4.6. Predictive Biomarkers

            14.4.7. Pharmacodynamic/Response Biomarkers

        14.5. Market Value Forecast By Disease Indication, 2017–2031

            14.5.1. Cancer

            14.5.2. Neurological Disorders

            14.5.3. Cardiovascular Disorders

            14.5.4. Infectious Diseases

            14.5.5. Immune Disorders

            14.5.6. Others

        14.6. Market Value Forecast By Country/Sub-region, 2017–2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Product & Service

            14.7.2. By Application

            14.7.3. By Type

            14.7.4. By Disease Indication

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Biomarkers Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast By Product & Service, 2017–2031

            15.2.1. Consumables

            15.2.2. Services

            15.2.3. Equipment

        15.3. Market Value Forecast By Application, 2017–2031

            15.3.1. Diagnostics

            15.3.2. Drug Discovery & Development

            15.3.3. Personalized Medicine

            15.3.4. Disease Risk Assessment

            15.3.5. Others

        15.4. Market Value Forecast By Type, 2017–2031

            15.4.1. Safety Biomarkers

            15.4.2. Susceptibility/Risk Biomarkers

            15.4.3. Diagnostic Biomarkers

            15.4.4. Prognostic Biomarkers

            15.4.5. Monitoring Biomarkers

            15.4.6. Predictive Biomarkers

            15.4.7. Pharmacodynamic/Response Biomarkers

        15.5. Market Value Forecast By Disease Indication, 2017–2031

            15.5.1. Cancer

            15.5.2. Neurological Disorders

            15.5.3. Cardiovascular Disorders

            15.5.4. Infectious Diseases

            15.5.5. Immune Disorders

            15.5.6. Others

        15.6. Market Value Forecast By Country/Sub-region, 2017–2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Product & Service

            15.7.2. By Application

            15.7.3. By Type

            15.7.4. By Disease Indication

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Share Analysis By Company (2022)

        16.2. Company Profiles

            16.2.1. Abbott Laboratories

                16.2.1.1. Company Overview

                16.2.1.2. Financial Overview

                16.2.1.3. Product Portfolio

                16.2.1.4. Business Strategies

                16.2.1.5. Recent Developments

            16.2.2. Agilent Technology

                16.2.2.1. Company Overview

                16.2.2.2. Financial Overview

                16.2.2.3. Product Portfolio

                16.2.2.4. Business Strategies

                16.2.2.5. Recent Developments

            16.2.3. Becton, Dickinson and Company

                16.2.3.1. Company Overview

                16.2.3.2. Financial Overview

                16.2.3.3. Product Portfolio

                16.2.3.4. Business Strategies

                16.2.3.5. Recent Developments

            16.2.4. Bio-Rad Laboratories

                16.2.4.1. Company Overview

                16.2.4.2. Financial Overview

                16.2.4.3. Product Portfolio

                16.2.4.4. Business Strategies

                16.2.4.5. Recent Developments

            16.2.5. BioMerieux SA (Astute Medical)

                16.2.5.1. Company Overview

                16.2.5.2. Financial Overview

                16.2.5.3. Product Portfolio

                16.2.5.4. Business Strategies

                16.2.5.5. Recent Developments

            16.2.6. Merck KGaA

                16.2.6.1. Company Overview

                16.2.6.2. Financial Overview

                16.2.6.3. Product Portfolio

                16.2.6.4. Business Strategies

                16.2.6.5. Recent Developments

            16.2.7. Qiagen NV

                16.2.7.1. Company Overview

                16.2.7.2. Financial Overview

                16.2.7.3. Product Portfolio

                16.2.7.4. Business Strategies

                16.2.7.5. Recent Developments

            16.2.8. Quanterix

                16.2.8.1. Company Overview

                16.2.8.2. Financial Overview

                16.2.8.3. Product Portfolio

                16.2.8.4. Business Strategies

                16.2.8.5. Recent Developments

            16.2.9. Quest Diagnostics

                16.2.9.1. Company Overview

                16.2.9.2. Financial Overview

                16.2.9.3. Product Portfolio

                16.2.9.4. Business Strategies

                16.2.9.5. Recent Developments

            16.2.10. Thermo Fisher Scientific Inc.

                16.2.10.1. Company Overview

                16.2.10.2. Financial Overview

                16.2.10.3. Product Portfolio

                16.2.10.4. Business Strategies

                16.2.10.5. Recent Developments

    List of Tables

    Table 01: Global Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 02: Global Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 03: Global Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 04: Global Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 05: Global Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 08: North America Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 09: North America Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 10: North America Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 11: Europe Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Europe Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 13: Europe Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 14: Europe Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 15: Europe Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 16: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 18: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 19: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 20: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 21: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 23: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 24: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 25: Latin America Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 26: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Product & Service, 2017–2031

    Table 28: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 29: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 30: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031

    List of Figures

    Figure 01: Global Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Biomarkers Market Value Share, by Product & Service, 2022

    Figure 03: Global Biomarkers Market Value Share, by Application, 2022

    Figure 04: Global Biomarkers Market Value Share, by Type, 2022

    Figure 05: Global Biomarkers Market Value Share, by Disease Indication, 2022

    Figure 06: Global Biomarkers Market Value Share, by Region, 2022

    Figure 07: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 08: Global Biomarkers Market Share Analysis, by Product & Service, 2022

    Figure 09: Global Biomarkers Market Share Analysis, by Product & Service, 2031

    Figure 10: Global Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 11: Global Biomarkers Market Value (US$ Mn), by Consumables, 2017–2031

    Figure 12: Global Biomarkers Market Value Share Analysis, by Consumables, 2022–2031

    Figure 13: Global Biomarkers Market Value (US$ Mn), by Services, 2017–2031

    Figure 14: Global Biomarkers Market Value Share Analysis, by Services, 2022–2031

    Figure 15: Global Biomarkers Market Value (US$ Mn), by Equipment, 2017–2031

    Figure 16: Global Biomarkers Market Value Share Analysis, by Equipment, 2022–2031

    Figure 17: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 18: Global Biomarkers Market Share Analysis, by Application, 2022

    Figure 19: Global Biomarkers Market Share Analysis, by Application, 2031

    Figure 20: Global Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 21: Global Biomarkers Market Value (US$ Mn), by Diagnostics, 2017–2031

    Figure 22: Global Biomarkers Market Value Share Analysis, by Diagnostics, 2022–2031

    Figure 23: Global Biomarkers Market Value (US$ Mn), by Drug Discovery & Development, 2017–2031

    Figure 24: Global Biomarkers Market Value Share Analysis, by Drug Discovery & Development, 2022–2031

    Figure 25: Global Biomarkers Market Value (US$ Mn), by Personalized Medicine, 2017–2031

    Figure 26: Global Biomarkers Market Value Share Analysis, by Personalized Medicine, 2022–2031

    Figure 27: Global Biomarkers Market Value (US$ Mn), by Disease Risk Assessment, 2017–2031

    Figure 28: Global Biomarkers Market Value Share Analysis, by Disease Risk Assessment, 2022–2031

    Figure 29: Global Biomarkers Market Value (US$ Mn), by Others, 2017–2031

    Figure 30: Global Biomarkers Market Value Share Analysis, by Others, 2022–2031

    Figure 31: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 32: Global Biomarkers Market Share Analysis, by Type, 2022

    Figure 33: Global Biomarkers Market Share Analysis, by Type, 2031

    Figure 34: Global Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 35: Global Biomarkers Market Value (US$ Mn), by Safety Biomarkers, 2017–2031

    Figure 36: Global Biomarkers Market Value Share Analysis, by Safety Biomarkers, 2022–2031

    Figure 37: Global Biomarkers Market Value (US$ Mn), by Susceptibility/Risk Biomarkers, 2017–2031

    Figure 38: Global Biomarkers Market Value Share Analysis, by Susceptibility/Risk Biomarkers, 2022–2031

    Figure 39: Global Biomarkers Market Value (US$ Mn), by Diagnostic Biomarkers, 2017–2031

    Figure 40: Global Biomarkers Market Value Share Analysis, by Diagnostic Biomarkers, 2022–2031

    Figure 41: Global Biomarkers Market Value (US$ Mn), by Prognostic Biomarkers, 2017–2031

    Figure 42: Global Biomarkers Market Value Share Analysis, by Prognostic Biomarkers, 2022–2031

    Figure 43: Global Biomarkers Market Value (US$ Mn), by Monitoring Biomarkers, 2017–2031

    Figure 44: Global Biomarkers Market Value Share Analysis, by Monitoring Biomarkers, 2022–2031

    Figure 45: Global Biomarkers Market Value (US$ Mn), by Predictive Biomarkers, 2017–2031

    Figure 46: Global Biomarkers Market Value Share Analysis, by Predictive Biomarkers, 2022–2031

    Figure 47: Global Biomarkers Market Value (US$ Mn), by Pharmacodynamic/Response Biomarkers, 2017–2031

    Figure 48: Global Biomarkers Market Value Share Analysis, by Pharmacodynamic/Response Biomarkers, 2022–2031

    Figure 49: Global Biomarkers Market Value (US$ Mn) Share Analysis, by Disease Indication, 2022–2031

    Figure 50: Global Biomarkers Market Share Analysis, by Disease Indication, 2022

    Figure 51: Global Biomarkers Market Share Analysis, by Disease Indication, 2031

    Figure 52: Global Biomarkers Market Attractiveness Analysis, by Disease Indication, 2023–2031

    Figure 53: Global Biomarkers Market Value (US$ Mn), by Cancer, 2017–2031

    Figure 54: Global Biomarkers Market Value Share Analysis, by Cancer, 2022–2031

    Figure 55: Global Biomarkers Market Value (US$ Mn), by Neurological Disorders, 2017–2031

    Figure 56: Global Biomarkers Market Value Share Analysis, by Neurological Disorders, 2022–2031

    Figure 57: Global Biomarkers Market Value (US$ Mn), by Cardiovascular Disorders, 2017–2031

    Figure 58: Global Biomarkers Market Value Share Analysis, by Cardiovascular Disorders, 2022–2031

    Figure 59: Global Biomarkers Market Value (US$ Mn), by Infectious Diseases, 2017–2031

    Figure 60: Global Biomarkers Market Value Share Analysis, by Infectious Diseases, 2022–2031

    Figure 61: Global Biomarkers Market Value (US$ Mn), by Immune Disorders, 2017–2031

    Figure 62: Global Biomarkers Market Value Share Analysis, by Immune Disorders, 2022–2031

    Figure 63: Global Biomarkers Market Value (US$ Mn), by Others, 2017–2031

    Figure 64: Global Biomarkers Market Value Share Analysis, by Others, 2022–2031

    Figure 65: Global Biomarkers Market Value Share Analysis, by Region, 2022–2031

    Figure 66: Global Biomarkers Market Share Analysis, by Region, 2022

    Figure 67: Global Biomarkers Market Share Analysis, by Region, 2031

    Figure 68: Global Biomarkers Market Attractiveness Analysis, by Region, 2023–2031

    Figure 69: North America Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 70: North America Biomarkers Market Value Share Analysis, by Country, 2022–2031

    Figure 71: North America Biomarkers Market Attractiveness Analysis, by Country, 2023–2031

    Figure 72: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 73: North America Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 74: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 75: North America Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 76: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 77: North America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 78: North America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 79: North America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 80: Europe Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 81: Europe Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 82: Europe Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 83: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 84: Europe Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 85: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 86: Europe Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 87: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 88: Europe Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 89: Europe Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 90: Europe Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 91: Asia Pacific Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 92: Asia Pacific Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 93: Asia Pacific Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 94: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 95: Asia Pacific Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 96: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 97: Asia Pacific Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 98: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 99: Asia Pacific Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 100: Asia Pacific Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 101: Asia Pacific Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 102: Latin America Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 103: Latin America Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 104: Latin America Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 105: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 106: Latin America Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 107: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 108: Latin America Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 109: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 110: Latin America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 111: Latin America Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 112: Latin America Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 113: Middle East & Africa Biomarkers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 114: Middle East & Africa Biomarkers Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 115: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 116: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Product & Service, 2022–2031

    Figure 117: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Product & Service, 2023–2031

    Figure 118: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Application, 2022–2031

    Figure 119: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Application, 2023–2031

    Figure 120: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 121: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 122: Middle East & Africa Biomarkers Market Value (US$ Mn) Share Analysis, by Type, 2022–2031

    Figure 123: Middle East & Africa Biomarkers Market Attractiveness Analysis, by Type, 2023–2031

    Figure 124: Biomarkers Market: Company Share Analysis, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved